Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis

A multi-center, prospective cohort study in Japan

Hayato Yamazaki, Fumio Hirano, Tsutomu Takeuchi, Koichi Amano, Jun Kikuchi, Mari Kihara, Waka Yokoyama, Takahiko Sugihara, Kenji Nagasaka, Hiroyuki Hagiyama, Yoshinori Nonomura, Ryoko Sakai, Michi Tanaka, Ryuji Koike, Toshihiro Nanki, Hitoshi Kohsaka, Nobuyuki Miyasaka, Masayoshi Harigai

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To evaluate association of clinical remission at month 6 with functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis (RA). Methods: This 12-month prospective, multicenter cohort study enrolled 168 patients with RA who started abatacept. Outcomes were assessed using composite measures, quality of life indices, and the van der Heijde-modified total Sharp score (mTSS). The logistic regression analysis was applied to identify factors associated with outcomes and their odds ratios (OR) with 95% confidence interval (95% CI). Results: At month 6 and 12, 21.4% and 26.2% of the patients achieved Simplified Disease Activity Index (SDAI) remission (SDAI <3.3), and 40.6% and 41.7% achieved Health Assessment Questionnaire-Disability Index (HAQ-DI <0.5) remission. Among 129 patients whose mTSS progression was evaluated at month 12, 83 (64.3%) achieved structural remission (ΔmTSS ≤0.5 for 12 months). SDAI remission at month 6 was identified as a significant predictor of both functional (OR, 3.732; 95% CI, 1.328–10.489) and structural remissions (OR, 4.301; 95% CI, 1.298–14.243) at month 12 after adjusting for covariates. Conclusions: Aiming for SDAI remission at month 6 is an appropriate strategy to obtain good functional and structural outcomes at month 12.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalModern Rheumatology
DOIs
Publication statusAccepted/In press - 2016 Dec 9

Fingerprint

Rheumatoid Arthritis
Japan
Cohort Studies
Prospective Studies
Odds Ratio
ametantrone
Confidence Intervals
Therapeutics
Multicenter Studies
Logistic Models
Regression Analysis
Quality of Life
Abatacept
Health

Keywords

  • Abatacept
  • Outcome assessment
  • Remission
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis : A multi-center, prospective cohort study in Japan. / Yamazaki, Hayato; Hirano, Fumio; Takeuchi, Tsutomu; Amano, Koichi; Kikuchi, Jun; Kihara, Mari; Yokoyama, Waka; Sugihara, Takahiko; Nagasaka, Kenji; Hagiyama, Hiroyuki; Nonomura, Yoshinori; Sakai, Ryoko; Tanaka, Michi; Koike, Ryuji; Nanki, Toshihiro; Kohsaka, Hitoshi; Miyasaka, Nobuyuki; Harigai, Masayoshi.

In: Modern Rheumatology, 09.12.2016, p. 1-8.

Research output: Contribution to journalArticle

Yamazaki, Hayato ; Hirano, Fumio ; Takeuchi, Tsutomu ; Amano, Koichi ; Kikuchi, Jun ; Kihara, Mari ; Yokoyama, Waka ; Sugihara, Takahiko ; Nagasaka, Kenji ; Hagiyama, Hiroyuki ; Nonomura, Yoshinori ; Sakai, Ryoko ; Tanaka, Michi ; Koike, Ryuji ; Nanki, Toshihiro ; Kohsaka, Hitoshi ; Miyasaka, Nobuyuki ; Harigai, Masayoshi. / Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis : A multi-center, prospective cohort study in Japan. In: Modern Rheumatology. 2016 ; pp. 1-8.
@article{979404cc69854c9999b6017c618154c4,
title = "Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japan",
abstract = "Objective: To evaluate association of clinical remission at month 6 with functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis (RA). Methods: This 12-month prospective, multicenter cohort study enrolled 168 patients with RA who started abatacept. Outcomes were assessed using composite measures, quality of life indices, and the van der Heijde-modified total Sharp score (mTSS). The logistic regression analysis was applied to identify factors associated with outcomes and their odds ratios (OR) with 95{\%} confidence interval (95{\%} CI). Results: At month 6 and 12, 21.4{\%} and 26.2{\%} of the patients achieved Simplified Disease Activity Index (SDAI) remission (SDAI <3.3), and 40.6{\%} and 41.7{\%} achieved Health Assessment Questionnaire-Disability Index (HAQ-DI <0.5) remission. Among 129 patients whose mTSS progression was evaluated at month 12, 83 (64.3{\%}) achieved structural remission (ΔmTSS ≤0.5 for 12 months). SDAI remission at month 6 was identified as a significant predictor of both functional (OR, 3.732; 95{\%} CI, 1.328–10.489) and structural remissions (OR, 4.301; 95{\%} CI, 1.298–14.243) at month 12 after adjusting for covariates. Conclusions: Aiming for SDAI remission at month 6 is an appropriate strategy to obtain good functional and structural outcomes at month 12.",
keywords = "Abatacept, Outcome assessment, Remission, Rheumatoid arthritis",
author = "Hayato Yamazaki and Fumio Hirano and Tsutomu Takeuchi and Koichi Amano and Jun Kikuchi and Mari Kihara and Waka Yokoyama and Takahiko Sugihara and Kenji Nagasaka and Hiroyuki Hagiyama and Yoshinori Nonomura and Ryoko Sakai and Michi Tanaka and Ryuji Koike and Toshihiro Nanki and Hitoshi Kohsaka and Nobuyuki Miyasaka and Masayoshi Harigai",
year = "2016",
month = "12",
day = "9",
doi = "10.1080/14397595.2016.1259715",
language = "English",
pages = "1--8",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis

T2 - A multi-center, prospective cohort study in Japan

AU - Yamazaki, Hayato

AU - Hirano, Fumio

AU - Takeuchi, Tsutomu

AU - Amano, Koichi

AU - Kikuchi, Jun

AU - Kihara, Mari

AU - Yokoyama, Waka

AU - Sugihara, Takahiko

AU - Nagasaka, Kenji

AU - Hagiyama, Hiroyuki

AU - Nonomura, Yoshinori

AU - Sakai, Ryoko

AU - Tanaka, Michi

AU - Koike, Ryuji

AU - Nanki, Toshihiro

AU - Kohsaka, Hitoshi

AU - Miyasaka, Nobuyuki

AU - Harigai, Masayoshi

PY - 2016/12/9

Y1 - 2016/12/9

N2 - Objective: To evaluate association of clinical remission at month 6 with functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis (RA). Methods: This 12-month prospective, multicenter cohort study enrolled 168 patients with RA who started abatacept. Outcomes were assessed using composite measures, quality of life indices, and the van der Heijde-modified total Sharp score (mTSS). The logistic regression analysis was applied to identify factors associated with outcomes and their odds ratios (OR) with 95% confidence interval (95% CI). Results: At month 6 and 12, 21.4% and 26.2% of the patients achieved Simplified Disease Activity Index (SDAI) remission (SDAI <3.3), and 40.6% and 41.7% achieved Health Assessment Questionnaire-Disability Index (HAQ-DI <0.5) remission. Among 129 patients whose mTSS progression was evaluated at month 12, 83 (64.3%) achieved structural remission (ΔmTSS ≤0.5 for 12 months). SDAI remission at month 6 was identified as a significant predictor of both functional (OR, 3.732; 95% CI, 1.328–10.489) and structural remissions (OR, 4.301; 95% CI, 1.298–14.243) at month 12 after adjusting for covariates. Conclusions: Aiming for SDAI remission at month 6 is an appropriate strategy to obtain good functional and structural outcomes at month 12.

AB - Objective: To evaluate association of clinical remission at month 6 with functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis (RA). Methods: This 12-month prospective, multicenter cohort study enrolled 168 patients with RA who started abatacept. Outcomes were assessed using composite measures, quality of life indices, and the van der Heijde-modified total Sharp score (mTSS). The logistic regression analysis was applied to identify factors associated with outcomes and their odds ratios (OR) with 95% confidence interval (95% CI). Results: At month 6 and 12, 21.4% and 26.2% of the patients achieved Simplified Disease Activity Index (SDAI) remission (SDAI <3.3), and 40.6% and 41.7% achieved Health Assessment Questionnaire-Disability Index (HAQ-DI <0.5) remission. Among 129 patients whose mTSS progression was evaluated at month 12, 83 (64.3%) achieved structural remission (ΔmTSS ≤0.5 for 12 months). SDAI remission at month 6 was identified as a significant predictor of both functional (OR, 3.732; 95% CI, 1.328–10.489) and structural remissions (OR, 4.301; 95% CI, 1.298–14.243) at month 12 after adjusting for covariates. Conclusions: Aiming for SDAI remission at month 6 is an appropriate strategy to obtain good functional and structural outcomes at month 12.

KW - Abatacept

KW - Outcome assessment

KW - Remission

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85006105959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006105959&partnerID=8YFLogxK

U2 - 10.1080/14397595.2016.1259715

DO - 10.1080/14397595.2016.1259715

M3 - Article

SP - 1

EP - 8

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

ER -